Biotechnology Analysis & Statistics, July 2014 (p30)

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Publishers

All regions

871-900 of about 2 400 reports

Purchase Reports From Reputable Market Research Publishers

Anti-CD33 Antibody -Pipeline Insights, 2014

Anti-CD33 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD33 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD37 Antibody -Pipeline Insights, 2014

Anti-CD37 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD37 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD38 Antibody -Pipeline Insights, 2014

Anti-CD38 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD38 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD4 Antibody -Pipeline Insights, 2014

Anti-CD4 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD4 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD40 Antibody -Pipeline Insights, 2014

Anti-CD40 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD40 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD52 Antibody -Pipeline Insights, 2014

Anti-CD52 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD52 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD6 Antibody -Pipeline Insights, 2014

Anti-CD6 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD6 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD70 Antibody -Pipeline Insights, 2014

Anti-CD70 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD70 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD80 Antibody -Pipeline Insights, 2014

Anti-CD80 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD80 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CD95 Antibody -Pipeline Insights, 2014

Anti-CD95 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CD95 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-CS1 Antibody -Pipeline Insights, 2014

Anti-CS1 Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-CS1 Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biopharmaceutical
Anti-Dickkopf-1 (Dkk-1) Antibody -Pipeline Insights, 2014

Anti-Dickkopf-1 (Dkk-1) Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-Dickkopf-1 (Dkk-1) Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective ...

  • Industries : Biopharmaceutical
Anti-Mucin 1 (MUC1) Antibody -Pipeline Insights, 2014

Anti-Mucin 1 (MUC1) Antibody -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Anti-Mucin 1 (MUC1) Antibody-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of ...

  • Industries : Biopharmaceutical
ATP Binding Cassette Sub Family B member 1 (ABCB1 or P-Glycoprotein or P-gp) Inhibitors -Pipeline Insights, 2014

ATP Binding Cassette Sub Family B member 1 (ABCB1 or P-Glycoprotein or P-gp) Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“ATP Binding Cassette Sub Family B member 1 (ABCB1 or P-Glycoprotein or P-gp) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs ...

  • Industries : Biopharmaceutical
Bone Morphogenetic Protein (BMP) Receptor Activators -Pipeline Insights, 2014

Bone Morphogenetic Protein (BMP) Receptor Activators -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Bone Morphogenetic Protein (BMP) Receptor Activators-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). ...

  • Industries : Biopharmaceutical
Broad Spectrum Chemokine Inhibitors (BSCIs) -Pipeline Insights, 2014

Broad Spectrum Chemokine Inhibitors (BSCIs) -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Broad Spectrum Chemokine Inhibitors (BSCIs)-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key ...

  • Industries : Biological Therapy
B-Cell Activating Factor (BAFF) Inhibitors -Pipeline Insights, 2014

B-Cell Activating Factor (BAFF) Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“B-Cell Activating Factor (BAFF) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key ...

  • Industries : Biological Therapy
Bcl-w Protein Inhibitors -Pipeline Insights, 2014

Bcl-w Protein Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Bcl-w Protein Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the ...

  • Industries : Biopharmaceutical
Bcl-xL Protein Inhibitors -Pipeline Insights, 2014

Bcl-xL Protein Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Bcl-xL Protein Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the ...

  • Industries : Biopharmaceutical
CD4+ T cell Activators -Pipeline Insights, 2014

CD4+ T cell Activators -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“CD4+ T cell Activators-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biological Therapy
CD8+ T cell Activators -Pipeline Insights, 2014

CD8+ T cell Activators -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“CD8+ T cell Activators-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report ...

  • Industries : Biological Therapy
Chemokine (C-C Motif) Ligand 2 (CCL2 or Monocyte Chemotactic Protein-1) Inhibitors -Pipeline Insights, 2014

Chemokine (C-C Motif) Ligand 2 (CCL2 or Monocyte Chemotactic Protein-1) Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Chemokine (C-C Motif) Ligand 2 (CCL2 or Monocyte Chemotactic Protein-1) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across ...

  • Industries : Biological Therapy
Chemokine Receptor Antagonists -Pipeline Insights, 2014

Chemokine Receptor Antagonists -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Chemokine Receptor Antagonists-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of ...

  • Industries : Biological Therapy
Cholesterylester Transfer Protein (CETP) Inhibitors -Pipeline Insights, 2014

Cholesterylester Transfer Protein (CETP) Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Cholesterylester Transfer Protein (CETP) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). ...

  • Industries : Biopharmaceutical
DNA Polymerase Alpha Inhibitors -Pipeline Insights, 2014

DNA Polymerase Alpha Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“DNA Polymerase Alpha Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective ...

  • Industries : Genomics
DNA Polymerase Beta Inhibitors -Pipeline Insights, 2014

DNA Polymerase Beta Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“DNA Polymerase Beta Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of ...

  • Industries : Genomics
DNA-Dependent RNA Polymerase Inhibitors -Pipeline Insights, 2014

DNA-Dependent RNA Polymerase Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“DNA-Dependent RNA Polymerase Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective ...

  • Industries : Genomics
Endothelin Converting Enzyme (ECE) Inhibitors -Pipeline Insights, 2014

Endothelin Converting Enzyme (ECE) Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Endothelin Converting Enzyme (ECE) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A ...

  • Industries : Biopharmaceutical
Epithelial Cell Adhesion Molecule (EpCAM or CD326) Inhibitors -Pipeline Insights, 2014

Epithelial Cell Adhesion Molecule (EpCAM or CD326) Inhibitors -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Epithelial Cell Adhesion Molecule (EpCAM or CD326) Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of ...

  • Industries : Biopharmaceutical
Factor IX -Pipeline Insights, 2014

Factor IX -Pipeline Insights, 2014

  • $ 1 250
  • Industry report
  • July 2014
  • by Delve Insight

SUMMARY DelveInsight's,“Factor IX-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish ...

  • Industries : Biopharmaceutical

About 100 Companies

Read our Company Profiles

GlaxoSmithKline P.L.C.

United States

Johnson and Johnson

United States

Life Technologies Corp.

United States

Illumina Inc.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.